Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Cambrex Corporation (NYSE: CBM ... 2014. Highlights , Second quarter ... the same period last year. , Second quarter EBITDA ... the same period last year (see table at the end ... increased, excluding the impact of foreign currency, to between 13% ...
(Date:7/31/2014)... 2014 Food and natural product ... for food alternatives that offer variety, as well ... ingredient market has numerous players operating in the ... Force Technology (VFT). VFT is a science-driven ... patterns, all tested to produce stable, effective and ...
(Date:7/31/2014)... July 31, 2014 Nearly 20,000 medical professionals ... Annual Meeting & Clinical Lab Expo in ... never-before-seen breakthroughs in diagnostic research and technology that will ... As of Wednesday, July 30, more than ... Meeting & Clinical Lab Expo, with more than 10,000 ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2
... Meeting, DEERFIELD, Ill., May 6 The Board ... today announced a quarterly,dividend and votes taken at the ... Board of Directors declared a quarterly dividend of $0.2175,per ... continuation of,the current rate. The quarterly dividend is payable ...
... May 6 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will ... on Tuesday, May 13th at 10:40 AM Pacific Time ... audio broadcast over the,Internet available at http://ir.sigmaaldrich.com . ... For the webcast on, http://ir.sigmaaldrich.com users will need ...
... May 6 There are a lot of steps,between ... organization,s,sales force must be involved with many of those ... successful re-launch effort,according to a study by benchmarking leader ... sales force? Half of the companies that,participated in the ...
Cached Biology Technology:Invigorated Sales Force Key to a Successful Re-Launch 2
(Date:7/31/2014)... noise alters how the brain processes speech, potentially ... to neuroscientists at The University of Texas at ... in Ear and Hearing , researchers demonstrated ... affects the brain,s recognition of speech sounds. , ... the population, affecting an estimated 15 percent of ...
(Date:7/31/2014)... The enormous conflagration known as the Rim Fire was ... among mature trees, when it entered the backcountry of ... August 2013. But inside the park, the battle began ... management decisions and drought can combine to fuel large, ... park, it eventually encountered lands where fire had been ...
(Date:7/31/2014)... or fat cells, are inherently different. Each of these ... own role in metabolism. In the human body, white ... primary function is energy storage. On the other hand, ... are only found in a few places in the ... type of brown adipocytes, appear mixed with brown adipocytes ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Hope for the overweight 2
... researchers have discovered that the Chlamydia bacterium, which causes ... with plants. That shared evolutionary heritage, which is not ... target for development of an effective cure for Chlamydia ... and plants had been proposed by others," said Thomas ...
... administered intravenously could be used as an agent to ... ionizing radiation in the event of large-scale exposure from ... study presented today by University of Pittsburgh researchers at ... Therapeutic Radiology and Oncology (ASTRO) in Philadelphia. , "Ionizing ...
... since the development of highly active antiretroviral therapy (or HAART) ... do so well that, according to blood tests, their immune ... studies from Rockefeller University and the Aaron Diamond AIDS Research ... tissues may never rebound, suggesting the need for additional ways ...
Cached Biology News:Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 3Intravenous gene therapy protects normal tissue of mice during whole-body radiation 2HIV-1 kills immune cells in the gut that may never bounce back 2HIV-1 kills immune cells in the gut that may never bounce back 3